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Abstract
Despite the chronic and increasingly prevalent nature of actinic keratosis (AK) and existing evidence supporting assess-
ment of the entire cancerization field during clinical management, a standardized definition of the AK field to aid in the
understanding and characterization of the disease is lacking. The objective of this review was to present and appraise
the available evidence describing the AK cancerization field, with the aim of determining a precise definition of the AK
field in terms of its molecular (including genetic and immunological), histological and clinical characteristics. Eight Euro-
pean dermatologists collaborated to conduct a review and expert appraisal of articles detailing the characteristics of the
AK field. Articles published in English before August 2016 were identified using PubMed and independently selected for
further assessment according to predefined preliminary inclusion and exclusion criteria. In addition, a retrospective audit
of patients with AK was performed to define the AK field in clinical terms. A total of 32 review articles and 47 original
research articles provided evidence of sun-induced molecular (including genetic and immunological) and histological
skin changes in the sun-exposed area affected by AK. However, the available literature was deemed insufficient to inform
a clinical definition of the AK field. During the retrospective audit, visible signs of sun damage in 40 patients with AK were
assessed. Telangiectasia, atrophy and pigmentation disorders emerged as ‘reliable or very reliable’ indicators of AK field
based on expert opinion, whereas ‘sand paper’ was deemed a ‘moderately reliable’ indicator. This literature review has
revealed a significant gap of evidence to inform a clinical definition of the AK field. Therefore, the authors instead pro-
pose a clinical definition of field cancerization based on the identification of visible signs of sun damage that are reliable
indicators of field cancerization based on expert opinion.
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Introduction
Actinic keratosis (AK) is a chronic and prevalent disease affect-
ing areas of sun-exposed skin1 where visible and subclinical,
non-visible lesions coexist. This area of sun-damaged skin is
prone to the development of further visible AK lesions and sun-
related skin cancer and is known by many as ‘field canceriza-
tion’.2
The concept of field cancerization was first introduced by
Slaughter and colleagues in 1953 when looking at oral squamous
cell carcinoma (SCC), to describe histologically abnormal sur-
rounding tissue, which would explain the appearance of addi-
tional tumours within the field.3 Since its first use, this concept
has been described in many different organ systems, including
head and neck, lung, vulva, oesophagus, cervix, breast, colon,
bladder and skin.4
In AK, field cancerization occurs as a result of neoplastic
changes induced by ultraviolet (UV) light across the whole sun-
exposed field of the skin. Various AK stages can coexist within
the cancerized field, which have become better characterized
with the development of new imaging tools, such as confocal
microscopy.2 These stages include individual UV-damaged ker-
atinocytes, subclinical non-visible lesions, early and late lesions,
and in some cases, invasive SCC.2
Despite common usage of the term field or field cancerization
and the concept being generally accepted, a precise and consis-
tent definition of the AK field is lacking.5 Without a clear defini-
tion of the field to aid in the understanding and characterization
of the disease, clinicians are presented with a challenge in classi-
fying and therefore assessing the options for the management of
AK.
Given this background, the purpose of this review was to
examine the available evidence that describes the AK field,
through a systematic review and expert appraisal of the existing
literature, to inform a robust definition in terms of the molecu-
lar (including genetic and immunological), histological and clin-
ical changes that take place.
Methodology
A committee was established, consisting of eight expert derma-
tologists from five European countries. One of the experts
defined the criteria for a systematic assessment of the literature
relating to the clinical, histological and molecular/genetic/im-
munological characteristics of the AK field. The search strings
used are shown in Table 1. The search was carried out in
PubMed and limited to articles in English. Articles published
before 31 August 2016 were searched with no limits placed on
the starting date.
Articles were independently selected for further assessment by
one of the experts according to predefined preliminary inclusion
and exclusion criteria. Articles were included if one or more of
the following criteria were met: field cancerization was men-
tioned in the title; field treatment was covered; the genetics of
field disease, AK and SCC were covered; or the article was a pub-
lished treatment guideline. Articles were excluded from review if
they did not refer to field cancerization or were deemed irrele-
vant to informing a field definition; discussed treatment of
specific lesions, melanoma or quality of life only; or related to
techniques for modulating pain regarding certain treatments.
The articles selected for further assessment were distributed
for review between the experts. Each expert summarized the key
evidence that could inform the description of the characteristics
of the AK field from their assigned articles. Clinical, histological
and molecular/genetic/immunological evidence was captured
separately in a standardized template. Experts could exclude arti-
cles that did not address field cancerization in AK.
Templates from all expert reviewers were collated. Statements,
based on the strongest and most consistent findings from the lit-
erature search in terms of molecular/genetic/immunological,
histological and clinical evidence, were developed (Table 2, left
column). These statements were assessed by all experts and
refined at a face-to-face meeting until expert agreement was
reached on the summary statements that were best to inform a
definition of the AK field from a molecular/genetic/immunologi-
cal, histological and clinical perspective (Table 2, right column).
Due to the limited evidence existing in the literature to inform
a clinical definition, the experts met again to define the AK field





1 ‘actinic keratosis’[All Fields] 2552
2 ‘field cancerization’[All Fields] OR ‘field
cancerisation’[All Fields] OR ‘field-
cancerized’[All Fields] OR ‘skin field
cancerization’[All Fields]
511
3 field[All Fields] AND cancerization[All Fields] 533
4 (‘actinically damaged skin’ [All Fields] OR
‘photodamaged skin’ [All Fields]OR ‘sun
damaged skin’[All Fields]) OR (subclinical[All
Fields] AND photodamage[All Fields])
807
5 (‘skin’[MeSH Terms] OR ‘skin’[All Fields])




6 1 AND 2 83
7 1 AND 3 73
8 1 AND 4 89
9 1 AND 5 7
10 6 OR 7 OR 8 OR 9 166
11 (‘genetic therapy’[MeSH Terms] OR
(‘genetic’[All Fields] AND ‘therapy’[All Fields])
OR ‘genetic therapy’[All Fields] OR
‘genetic’[All Fields]) AND ‘actinic
keratosis’[All Fields]
93
12 molecular[All Fields] AND ‘actinic
keratosis’[All Fields]
137
13 10 OR 11 OR 12 344
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in clinical terms based on their experience in clinical practice.
Prior to the meeting, all experts carried out a retrospective audit,
listing all visible signs of sun damage identifiable in their last five
patients with AK (40 patients in total). At the meeting, these
signs were ranked on their reliability as indicators of AK field
disease on a scale from 1 to 9, where 1 represents ‘strongly dis-
agree’ and 9 represents ‘strongly agree’ (Fig. 1). If at least 5/8
experts voted on a visible sign being reliable/very reliable (scores
7–9) or moderately reliable (scores 4–6) and unanimous agree-
ment was reached following a moderated discussion, that visible
sign of sun damage was accepted as a reliable indicator of AK
field. Accepted reliable visible signs of sun damage were used to
provide a clinical definition of AK field. Recommendations for
disease management in the presence of the signs of sun damage
indicative of field cancerization were then made.
Results
The numbers of studies originally identified, assessed and finally
included in the review are summarized in Fig. 2. A total of 32
review articles and 47 original research articles were included
and reviewed. A detailed summary of the evidence from all origi-
nal research articles, broadly categorized into molecular/genetic/
immunological, histological and clinical and ‘infraclinical’ (with
imaging techniques allowing visualization of deep layers of the
skin) evidence, is presented in Table 3. The key findings are
summarized below.
Literature review
Molecular/genetic/immunological evidence Twenty-nine stud-
ies provided molecular/genetic/immunological evidence relevant
to inform a field definition in AK (Table 3).6–34
Evidence from the literature suggests that UVB-induced
molecular/genetic/immunological changes take place in the
entire anatomical area affected by AK and can lead to abnormal-
ities in keratinocyte proliferation.35
For instance, several signalling pathways are affected in the
UVB-induced transformation from normal skin to AK and SCC.
In addition, downregulation of the Notch effector CSL (also
known as RBP-Jj) in dermal fibroblasts is sufficient for cancer-
associated fibroblast (CAF) activation and ensuing keratinocyte-
derived tumours. This activity has been observed in stromal
fibroblasts of premalignant AK lesions and in situ SCCs.6,13
Alterations in the RAF-1/MER/ERK cell survival pathway have
also been observed.21 Furthermore, UVB-induced changes in
gene/protein expression play a role in the development of AK
and SCC. These include changes affecting DNA damage repair
responses,8,16,21 loss of heterozygosity in chromosomes 6 and
Table 2 Literature summary statements defining AK field before and after critical appraisal




• UV radiation induces a cascade of molecular signalling
events at a cellular level that produces inflammation,
immunosuppression, failure of apoptosis and aberrant
differentiation, resulting in mutagenesis and carcinogenesis
• UV radiation has been shown to induce a cascade of
molecular signalling events at a cellular level that produces
inflammation and immunosuppression, which can lead to
mutagenesis and result in failure of apoptosis, aberrant
differentiation and carcinogenesis
• Changes in the expression of the genes involved in these
processes (e.g. tumour suppressor genes, most notably
p53) occur frequently within the sun-exposed areas and are
the first manifestation of the process known as ‘field
cancerization’
• Mutations and changes in expression of genes involved in
these processes (e.g. tumour suppressor genes, most
frequently cited p53) occur frequently within sun-exposed
areas. This is a manifestation of the concept known as ‘field
cancerization’
• Morphologically normal, sun-exposed tissue surrounding
actinic keratosis (AK) and squamous cell carcinoma (SCC)
lesions often show similarly altered expression of some of
these genes, suggesting the existence of a disease
continuum from the initial molecular changes that take place
in individual cells to AK to SCC
• Morphologically normal, sun-exposed tissue surrounding
actinic keratosis (AK) and squamous cell carcinoma (SCC)
lesions often show similarly altered expression of some of
these genes; this may suggest the existence of an
association between initial molecular changes that take
place in individual cells and the development of AK or SCC
Histological • Following the initial molecular changes, histopathological
changes characteristic of AK can be detected
• Histopathological changes known to be characteristic of AK
can be detected following molecular changes
• Changes include crowded, atypical, epidermal keratinocytes
with large, hyperchromatic and pleomorphic nuclei, some in
mitosis
• Histopathological changes include crowding of atypical,
epidermal keratinocytes with large, hyperchromatic and
pleomorphic nuclei, some in mitosis; some of these changes
can be seen in perilesional skin• Significant histological alterations, suggesting extensive
preneoplastic alterations are often present in sun-damaged
skin adjacent to visible AK lesions, providing further
evidence for ‘field cancerization’ and a disease continuum
Clinical • Visible AKs are most often seen on a background of sun-
damaged skin (e.g. dermatoheliosis with solar elastosis,
yellow discoloration, dyspigmentation, telangiectasias,
ephelides, lentigos, sagging skin)
• Visible AKs are most often seen on a background of
clinically sun-damaged skin. A clear definition and
consensus on what constitutes sun damage is lacking
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917,24 and alterations in tumour suppressor genes, including
p53,6,22,24,26,27,32,36 PTEN15,19 and p16INK4a and p14ARF.24
Microsatellite instability in chromosomes 6 and 9 has also been
observed in AK and SCC lesions.17,24
Many mutations and changes in gene expression are already
observed in photodamaged skin, becoming increasingly promi-
nent in AK and SCC. Therefore, photodamaged skin, AK and
SCC are thought to be part of a disease continuum correspond-
ing to field cancerization.37
Changes in intracellular signalling pathways, mediated by
DNA damage induced by oxidative stress, can lead to alterations
in cytokine regulation, inflammation, changes in T-cell
homoeostasis and immunosuppression.25,35 The innate immune
system, therefore, plays a key role in AK – the intense inflamma-
tory response includes a significant increase in T lymphocytes
and Langerhans cells.13,25,35 Based on the evidence above, pre-
liminary statements to define the AK field from a molecular/ge-
netic/immunological perspective were brought forward for
expert appraisal (Table 2, before critical appraisal column).
Histological evidence Eleven studies provided histological evi-
dence relevant to inform a field definition in AK (Table 3).36–46
These studies reported histological changes common to pho-
todamaged skin adjacent to visible AK lesions as well as visible
AK lesions, such as corneocytes, stratum corneum disruption,
dermal inflammatory cells, increased vascularity/dilated vessels
and solar elastosis. Keratinocyte pleomorphism and architectural
changes as well as nuclear morphometric alterations were also
common to both photodamaged skin and visible AK lesions, but
































1 2 3 4 5 6 7 8 9
How RELIABLE are these visible signs of sun-damage as indicators of AK field disease?
Please select the most appropriate score number (1-9) within each range
Figure 1 Visible signs of sun damage identified in retrospective audit of patients with AK.
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interpreted as providing evidence for a disease continuum from
photodamaged skin to AK corresponding to field canceriza-
tion.37
The fact that AKs are frequently found in the skin immedi-
ately surrounding cutaneous malignancies (SCCs, and less fre-
quently basal cell carcinomas and malignant melanomas) has
also been interpreted as providing additional evidence for field
cancerization.46
Based on the evidence above, preliminary statements to define
the AK field histologically were brought forward for expert
appraisal (Table 2, before critical appraisal column).
Clinical or ‘infraclinical’ evidence Fourteen studies provided
clinical or ‘infraclinical’ evidence relevant to inform a field defi-
nition in AK (Table 3).2,36,37,41–44,47–53
Only one study attempted to give a clinical definition of field
cancerization as ‘mild, moderate or severe, based on the degree to
which the surrounding skin [adjacent to visible AK lesions] pre-
sented mottled erythema and pigmentation, telangiectasia, sallow-
ness, laxity and a dry texture without fulfilling the definition of an
AK lesion’.47
The remaining studies reported on the usefulness of tradi-
tional imaging techniques, such as fluorescence and hyperspec-
tral imaging (HIS), or more modern imaging techniques,
including reflectance confocal microscopy (RCM) and optical
coherence tomography (OCT) to detect subclinical actinic
changes (i.e. field cancerization) in anatomical areas adjacent to
clinically visible AKs and other visible signs of photodamage
(e.g. mottled pigmentation, fine lines, sallowness, roughness,
facial erythema, telangiectasias, laxity, coarse wrinkles, dry tex-
ture).2,36,37,41–44,47–50,52,53
There was good concordance between diagnosis and grading
of AK (clinical and subclinical) performed with HIS, RCM or
OCT and histological analysis of biopsied tissue, suggesting that
these techniques provide a suitable, non-invasive alternative for
diagnosis.2,41–44,48,52,53 The usefulness of RCM to monitor
improvements in subclinical AK following treatment with field-
directed therapies was also reported.40,52,53
Based on the limited clinical evidence available, preliminary
statements to define the AK field clinically were brought forward
for expert appraisal (Table 2, ‘before expert appraisal’ column).
The need for a clear definition of visible clinical signs indicative
of AK field was identified, and a retrospective audit of visible
clinical signs of AK field was carried out to meet this need.
Clinical signs of AK field: retrospective audit results
Of all the visible signs of sun damage identified during the retro-
spective audit (Fig. 2), telangiectasia, atrophy and pigmentation
disorders emerged as ‘reliable or very reliable’ indicators of AK
field based on expert opinion. ‘Sand paper’ was deemed a ‘mod-
erately reliable’ indicator of AK field.
Discussion
There is a large body of evidence on the UVB-induced changes
that take place in the skin at a molecular/genetic/immunological
level and at a histological level that can form the basis for a defi-
nition of the AK field, as summarized by the statements in
Table 2. Following critical appraisal of the literature, however,
the authors agreed on some points needing clarification.
UV radiation has, indeed, been shown to induce a cascade of
molecular signalling events at a cellular level in the skin that pro-
duces inflammation and immunosuppression.6,13,21,35 A decrease
in innate immunity with ageing (immunosenescence) and sun
exposure is well characterized.54,55 These events can lead to muta-
genesis and result in failure of apoptosis, aberrant differentiation
and carcinogenesis,35 but it is important to emphasize that this is
not always the case as genetic make-up and environmental factors
all play a major role in determining the final outcome.54
Furthermore, multiple mutations and changes in gene expres-
sion have been identified in sun-exposed areas of the skin, many
of which have been shown to play a role in the development of
AK and SCC.8,16,17,24 The role of the tumour suppressor gene
p53 has been widely studied and reported.6,22,24,26,27,32,36 For this
reason, its importance may have been overemphasized. Many
other tumour suppressor genes are deregulated and also play a
crucial role in AK development,14,15,19,24 such as p16INK4a,
p14ARF and PTEN.15,19
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Figure 2 Study selection flow diagram.
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Table 3 Summary of original research publications relevant to inform a definition of AK field in molecular/immunological/genetic, histo-
logical and clinical terms
References Year Methodology Key findings
Clinical, histological and molecular
36 2012 • Patients with PD skin and multiple AK on the face
(n = 26) received three consecutive sessions of
MAL-PDT with red light (37 J/cm2), 1 month
apart
• All patients were evaluated for global photoaging,
mottled pigmentation, fine lines, sallowness,
roughness, facial erythema, telangiectasias and
coarse wrinkles
• Biopsies before and 3 months after the last treat-
ment session were taken from normal-appearing
skin on the field-cancerized area
• IHC stainings were performed for TP-53, procolla-
gen-I, MMP-1 and Tn-C
• Results demonstrate clinical and histological
improvement in field cancerization after multiple
sessions of MAL-PDT
• All clinical parameters improved and were statisti-
cally significant except coarse wrinkles
• The improvement of PD skin is explained by the
increase in new collagen deposition and a decrease
in solar elastosis
• A positive correlation of the histological parameter
‘extent of atypia’ and TP-53 before treatment was
noted based on the Pearson correlation test
(P = 0.002), which means that higher TP-53
expression was observed with higher amounts of
cellular atypia
• The decrease in severity and extent of keratinocyte
atypia associated with a decreased expression of
TP-53 suggest a reduced carcinogenic potential of
the sun-damaged area
Clinical
47 2016 • Multicentre, non-interventional, cross-sectional
study in three dermatology hospital departments
and seven private dermatology clinics which
enrolled 312 AK patients consecutively during
1 week
• Field cancerization defined as: mild, moderate or
severe, based on the degree to which the surround-
ing skin presented mottled erythema and pigmen-
tation telangiectasia, sallowness, laxity and a dry
texture without fulfilling the definition of an AK
lesion
• AK-affected regions (AKARs) defined as: single (1
AK lesion); scattered solitary lesions (2–4 AK
lesions); or multiple lesions (≥5 AK lesions)
• NMSC was previously reported in 51.0% of
patients and currently suspected in 9.4% of AK-
affected anatomical regions
• Lesions of AK were located rimarily on the face
(38.6%), scalp (12.8%) and hands (11.2%)
• AK commonly presented with multiple lesions
(38.6%) and field cancerization (38.5%)
• The prevalence of severe actinic damage (17.3% vs.
9.6%; P < 0.001) and intake of immunosuppres-
sive medication (29.0% vs. 2.0%) were higher in
hospital-treated vs. private practice-treated patients
• The majority of AK patients in Danish dermatology
clinics have a history of skin cancer, and NMSC is
suspected in almost 10% of AK-affected regions
51 1989 • This clinical study included 808 Caucasian Mary-
land watermen and examined the prevalence of
non-melanoma skin cancer in relation to age and
exposure to solar UVB radiation
• Prevalence of the three major types of non-mela-
noma skin neoplasms was analysed: SCC, BCC and
AK
• Average annual exposure to UVB radiation was
strongly correlated with the prevalence of SCC, but
not with the prevalence of BCC or AK
• This finding is consistent with dose saturation (pla-
teau in dose–response relationship) for the induc-
tion of BCC and AK in humans with high annual
exposure to UVB radiation
• Two small groups of apparently hypersusceptible
individuals were present in the population – one
group had SCC despite low annual exposure to
UVB radiation, and the other group had multiple
skin cancers despite average exposure to UVB radi-
ation
Infraclinical (imaging)
50 2016 • Small clinical study including patients (n = 10
male and 10 female, aged 58–80 years) affected by
AKs on sun-exposed skin
• 160 mg/g MAL was applied (under occlusion) on
lesions and perilesional areas for an; extension of
44 cm2
• After 3 months there was a significant 48% reduc-
tion in the fluorescence score in patients treated
with PDT but no change in fluorescence score in
untreated AK patients
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Table 3 Continued
References Year Methodology Key findings
• The fluorescence extension and intensity of PpIX
emitted from the cells in each of 16 subareas of the
44 cm2 treatment area were measured and pho-
tographed
• Group 1 (n = 10): treated with two sessions of day-
light PDT at baseline and after 1 month
• Group 2 (n = 10): not treated with PDT and kept
the occlusion for 24 h, with the aim to prevent the
formation of PpIX
• The field of cancerization covered an area greater
than the 25 cm2 that is usually indicated for field-
directed treatment
• A control group of subjects without AK (n = 10),
who applied MAL on skin that was not sun-
exposed, showed a green fluorescence indicative of
skin without actinic damage
52 2015 • Case series of eight patients (1 female, 7 male, aged
56–82 years) with multiple clinical and subclinical
AK lesions
• Patients received field-directed 5-FU/SA once daily
for ≤6 weeks or until erosion and/or pain/bleeding
• Study aimed to test the applicability of RCM for
non-invasive monitoring of actinic field canceriza-
tion and detection of subclinical AK
• Complete clearance of clinical/subclinical AKs on
various body areas was shown in most patients
using RCM
• RCM allows non-invasive monitoring of treatment
response in vivo and permits early detection of sub-
clinical AK, increasing diagnostic accuracy com-
pared with clinical evaluation alone
• Topical field-directed 5-FU/SA monitored with
RCM is a promising management approach for
subclinical AKs
49 2013 • This pilot study included patients clinically diag-
nosed with bilateral field cancerization associated
with AK and/or photodamage on the face (treat-
ment area not defined)
• PDT was used for treatment (nano-ALA and
MAL), whereas the fluorescence of the correspond-
ing photosensitizer was used to evaluate the time
evolution of field cancerization in a quantitative
way
• The half-life of field cancerization reduction was
43.3 days for nano-ALA and 34.3 days for MAL
• The efficacy of nano-ALA in treating skin field
cancerization is higher than that of MAL
• Use of nano-ALA represents a feasible routine tool
for detection, treatment and follow-up of AK and
skin photodamage
53 2010 • Small clinical study included 11 otherwise healthy
Caucasian volunteers (Fitzpatrick skin phototype II
–III; aged 59–77 years), with a clinical diagnosis of
AK of the face and scalp and signs of field cancer-
ization
• Study aimed to test the applicability of RCM for
non-invasive monitoring of actinic field canceriza-
tion and detection of subclinical AK
• RCM detected morphologic features of AK in both
clinical and subclinical AK; features were more pro-
nounced in clinical lesions
• The immunomodulatory response induced by
IMIQ 5% cream (used to ‘highlight’ subclinical
regions) was visualized by RCM
• RCM allows non-invasive monitoring of treatment
response in vivo and permits early detection of sub-
clinical AK, increasing diagnostic accuracy com-
pared with clinical evaluation alone
48 2007 • In this pilot study extension, participants (n = 112;
aged 40–86 years) had either normal, sun-damaged
or presence of AK on their forearm skin
• OCT images were obtained at two sun-protected
and two sun-exposed sites, with a subsequent
biopsy at each site
• Each site received dermatological evaluation, a his-
tological diagnosis and a solar elastosis score
• Significant differences in average attenuation values
were found between:
• Skin with minimal vs. skin with severe solar elasto-
sis (P < 0.0001)
• Undiseased skin vs. AK (P < 0.0001 using a gradi-
ent analysis)
• Using OCT image features, AK could be distin-
guished from undiseased skin with 86% sensitivity
and 83% specificity
Infraclinical (imaging) and histological
37 2016 • Study included participants (n = 20; mean age
64 years) with skin phototype I and II
• RCM was performed on two PD sites and one AK
lesion within a field of 25 cm2 on the left dorsal
forearm, followed by shave biopsies
• Individual corneocytes, stratum corneum disrup-
tion, dermal inflammatory cells, increased vascular-
ity/dilated vessels and solar elastosis were all
detected in PD sites and AK lesions
• AK lesions demonstrated parakeratosis, hyperker-
atosis, severe keratinocyte pleomorphism and
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Table 3 Continued
References Year Methodology Key findings
• Blinded evaluation of the histopathological and
RCM images using established parameters in AK
were performed retrospectively
architectural disruption, and the presence of epi-
dermal inflammatory cells
• PD sites demonstrated keratinocyte pleomorphism
and architectural disruption but less severe than in
AK
• A small subset of PD sites showed comparable ker-
atinocyte pleomorphism and architectural disrup-
tion to AK lesions
• The viable epidermis showed PD and AK to be part
of a disease continuum corresponding to field
cancerization
• Individual corneocytes, stratum corneum disrup-
tion, dermal inflammatory cells, increased vascular-
ity/dilated vessels and solar elastosis may be present
in PD; whereas, parakeratosis and hyperkeratosis
may represent the key to distinguishing AK from
PD using RCM
41 2016 • Single-arm, open-label, split-face study in males
with AK (n = 30; aged 67–93 years) attending a
hospital outpatient clinic
• A suspected AK lesion and the normal-appearing,
perilesional skin were imaged and biopsied for
histopathological analysis
• The results were compared with the clinical and a
blinded OCT diagnosis
• OCT had 100% (28/28) correlation with the clinical
diagnosis of AK and detected 73% (16/22) of
histopathologically confirmed subclinical lesions
from perilesional skin sites
• OCT was effective for the diagnosis of clinical and
subclinical AK; all lesions that were identified as
AK by OCT were histologically confirmed as AK or
SCC
40 2015 • This article describes field cancerization by RCM
and the changes induced by the application of 3%
diclofenac sodium gel in 2.5% hyaluronic acid
• Clinical examination, confocal microscopy and his-
tological study of clinically visible lesions and ‘nor-
mal-appearing’ adjacent skin before and after
treatment were examined
• RCM showed a decrease in scaling (P = 0.001) and
atypia of the honeycomb pattern (P = 0.001) after
2 weeks of treatment
• Changes in parakeratosis, inflammation and der-
mal collagen remodelling occurred
• Histology correlated with confocal features in AK
and subclinical AK
• RCM was useful in the evaluation of field cancer-
ization and monitoring of treatment response
43 2015 • A histopathological study selected 48 AKs and two
control areas (photodamaged and non-photoda-
maged skin)
• All areas were documented by RCM and biopsied
for histopathology
• One representative image of the epidermis was
selected for RCM and for histopathology and used
for side-by-side comparison
• The assessor chose which of two images displayed
more keratinocyte atypia
• Three evaluations were obtained for RCM and two
for histopathology
• Good interobserver correlation was obtained for
RCM and histopathology grading, with high con-
cordance between RCM and histopathology grad-
ing
• Expert rater scan consistently distinguish different
grades of cytological atypia
• Non-invasive RCM data from in vivo imaging can
be graded for keratinocyte atypia, comparable to
histopathological grading
42 2013 • This study used an objective, non-invasive, real-
time hyperspectral imaging system (HIS) in vivo
and included 52 clinical AKs in 12 patients
• In six patients, digital photographs were taken of
the naive AKs, and again after MAL-fluorescence
diagnosis which was used to teach HIS to find sub-
clinical lesions
• Biopsies were taken from clinical AKs, healthy-
looking skin and several suspected subclinical AKs
• HIS detected all clinically visible AKs (n = 52) and
numerous subclinical lesions
• The histopathology of the 33 biopsied lesions were
concordant with the HIS results showing either AK
(n = 28) or photodamage (n = 5)
• Of the 28 histopathologically confirmed AKs, 16
were subclinical. A specific diffuse reflectance spec-
trum of an AK and healthy skin was defined
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• In the other six patients, digital and hyperspectral
images were taken of the na€ıve AKs followed by
one biopsy/patient
• HIS offers a new, non-invasive method for early
detection of field cancerization
44 2007 • Caucasians (SPT I-III) with ≥1 AK lesion (n = 44)
were included in this study
• Evaluation consisted of clinical examination, RCM
and routine histology
• RCM evaluation parameters included parakerato-
sis, architectural disarray and keratinocyte pleo-
morphism
• 44 AKs were included in the final analysis, which
involved blinded evaluation by two independent
investigators
• 97.7% of all skin samples were identified as AK
using RCM
• 2.3% were incorrectly identified as normal skin by
RCM, while routine histology showed features con-
sistent with AK
• RCM may be a feasible alternative in the diagnosis
of AK and aid the differentiation against normal
skin, as well as in the detection of subclinical dis-
ease
Histological
46 2016 • A study using cutaneous specimens submitted to
the dermatopathology service assessed the presence
of histologically identified AKs in the tissue imme-
diately surrounding excision specimens of SCCs,
BCCs and MMs
• Field cancerization was demonstrated by the pres-
ence of AKs (i.e. field damage with malignant
potential) in the skin immediately surrounding
cutaneous malignancies
• AKs were observed significantly more frequently in
SCC specimens [57% (35/61)] than BCC [33% (21/
64)] or MM [25% (6/24)] specimens (P = 0.0125)
• Findings provide additional evidence for field
cancerization due to presence of field damage with
malignant potential in the skin immediately sur-
rounding cutaneous malignancies
45 2003 • A panel of dermatopathologists developed histolog-
ical criteria (atypia, inflammation, hyperkeratosis,
parakeratosis, dyskeratosis, epidermotropism and
loss of the granular layer) and diagnostic defini-
tions for the progression of lesions from early AK
to AK
• The criteria were applied to a sample of 335 histo-
logical slides from an ongoing chemoprevention
study
• A 10% sample of 35 slides was reread to assess
intrarater reliability
• Six of the 7 criteria demonstrated high reliability
(>85%)
• The total histological score, calculated using the 6
criteria, was found to significantly differentiate
between (blinded) biopsy location (normal, pre-
AK, AK and adjacent to SCC) and histological diag-
nosis (normal, pre-AK or early AK, AK and SCC)
• The total histological score is a reliable and valid
endpoint for assessing the efficacy of agents in skin
cancer chemoprevention studies
Histological and genetic
38 2004 • This clinical study included patients with a history
of chronic sun exposure and clinical features of AK
on sun-exposed surfaces of the upper extremities
(n = 51; aged 44–86 years)
• Computer-assisted image analysis was used to mea-
sure nuclear morphometric parameters, p53
expression, and proliferation markers in biopsies
taken from AK, sun-exposed and normal skin
• Histological analysis was performed to confirm
diagnosis of normal skin, sun-damaged skin and
AK
• Nuclear morphometry showed increases in nuclear
absorbance and irregularity of nuclear shape and
size during progression from normal skin to AK
• Proliferation markers included argyrophilic nucleo-
lar organizer (AgNOR) number and areas, which
were greater in AK than in normal and sun-
damaged skin, and Ki67 and p53 staining which
were greater in sun-damaged skin compared with
normal skin and greatest in AK lesions
• Progression from normal to sun-damaged skin to
AK was accompanied by increasingly abnormal val-
ues of nuclear DNA content, size, shape and vari-
ability, as well as increases in p53 expression, Ki67
labelling index, and nucleolar organizer size and
number
• Increased proliferation and p53 abnormalities pre-
ceded nuclear morphometric alterations in the pro-
gression towards AK
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39 1997 • Study recruited subjects via advertisements, flyers
and recontact from previous skin chemoprevention
trials
• Biopsies were collected from three groups: 78 sub-
jects with sun damage on forearms, 33 with AK on
forearms and 32 with previous SCC
• IHC was conducted with anti-p53 antibody; video-
prints were quantified manually
• There was a significant difference and a progres-
sively increasing mean p53 labelling index in total
epidermis (basal and suprabasal levels) between
upper medial arm skin and AK-adjacent, and
between AK and AK-adjacent skin; upper medial
arm skin was marginally different from non-sun-
exposed skin
• This pattern was also seen when epidermis was sep-
arated into basal and suprabasal levels; epidermal
p53 protein expression is associated with histologi-
cal evidence of chronic sun damage
• Clinical AKs appear primarily on sun-exposed areas
and sites adjacent to AKs may contain significant
histological alterations, suggesting extensive pre-
neoplastic alterations in sun-damaged skin
Molecular/genetic/immunological
6 2015 • Loss or downmodulation of the Notch effector CSL
(also known as RBP-Jj) in dermal fibroblasts is suf-
ficient for CAF activation and ensuing ker-
atinocyte-derived tumours
• The effects of CSL on senescence- and CAF-deter-
minant genes were investigated in stromal fibrob-
lasts from various organs
• Experiments were performed using mouse and
human tissue samples
• Stromal fibroblast senescence has been linked to an
increased incidence of many cancer types with age
• CSL, which halts the activation of CAF, is down-
modulated in stromal fibroblasts of premalignant
actinic keratosis lesions and in situ squamous cell
carcinomas, whereas p53 expression and function
are downmodulated only in the latter
• Relative to less advanced AK lesions, more wide-
spread stromal alterations around in situ SCCs are
likely to occur, as part of expanding cancer fields
• LCM analysis of stromal fibroblasts underlying
these lesions, as well as flanking skin, showed that
CSL levels were consistently reduced relative to an
external set of age- and site-matched skin samples
from other individuals. Importantly, p53 expres-
sion was also downregulated
• Concomitant loss of CSL and p53 overcomes
fibroblast senescence, enhances expression of CAF
effectors and promotes stromal and cancer cell
expansion
8 2015 • Immunohistochemistry was used to investigate
expression of WRN in formalin-fixed, paraffin
wax-embedded tissue specimens of 9 SCC, 15 AK,
11 BD and 11 normal-appearing peripheral tissue
samples
• Tissue samples were obtained from patients during
surgical resections
• WRN has DNA helicase activity and plays a role in
the recombination, replication and repair of DNA
Inactivating mutations in WRN lead to genetic
instability, the premature onset of age-related dis-
eases and cancer. Upregulation of WRN increases
proliferation and survival of cancer cells
• WRN expression was significantly increased in BD,
AK and SCC compared with normal controls, with
the mean WRN staining score being highest in BD,
followed by AK and SCC. However, age, sex and
sun exposure were not associated with WRN
expression
• To our knowledge, this is the first report to date
investigating the expression of WRN in skin can-
cers. The overtly high expression of WRN in pre-
malignant lesions and in in situ cancer, with
relatively low WRN expression in SCC, may indi-
cate that WRN contributes as a checkpoint for early
DNA damage response in skin tumorigenesis
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7 2015 • Genetic susceptibility to AK was assessed in a geno-
mewide association study
• A full body skin examination was performed in
3194 elderly individuals of north-western European
origin
• Physicians graded the number of AK using 4 sever-
ity levels (none, 1–3, 4–9 and ≥10)
• In multivariable regression analyses, the association
between 12 pigmentation-associated SNPs and AK
risk was evaluated
• IRF4, MC1R and TYR are involved in various kinds
of human pigmentation traits including eye, hair
and skin colour, tanning ability and freckling as
well as with skin cancer, including BCC, SCC and
melanoma of the skin
• IRF4, MC1R and TYR genes were identified as sig-
nificant risk factors for AK in the north-western
European study population
• After adjustments for skin colour, the strength and
significance of the genetic association was hardly
affected, indicating that the genetic effect is at least
partially independent of skin colour and having a
much stronger effect than skin colour on AK risk
• Overall, the study suggests that IRF4,MC1R and
TYR genes likely have pleiotropic effects, a combi-
nation of pigmentation and oncogenic functions,
resulting in an increased risk of AK
9 2014 • This study evaluated tumour angiogenesis and lym-
phangiogenesis in cancerous and precancerous
lesions of the eyelids using immunohistochemical
techniques
• Overall, 147 formalin-fixed, paraffin-embedded
samples were included. Most cases (n = 113) were
BCC: six were BSC, 10 were SCC and 18 were pre-
cancerous lesions such AK and BD
• The authors recorded the microvascular density of
these tumours using the marker CD-105, a specific
antibody against endoglin protein
• Neoplastic angiogenesis plays a key role in tumour
growth and spread
• Data analysis showed that the molecular factors
that control angiogenesis are expressed in high pro-
portions in the tumours studied and that this
expression is positively correlated with tumour
microvascular density
• Furthermore, correlations emerged with the mean
diameter of these tumours
• They also found differences in microvascular den-
sity between precancerous and cancerous eyelid
lesions
10 2014 • Analytical cross-sectional study that included 62
skin tumour samples (n = 49 malignant and 13
premalignant)
• High expression of COX-2 has been demonstrated
in various neoplasms
• F-2 expression was investigated using IHC
• COX-2 expression was found in: 16/17 (94%) SCC
samples; 28/32 (87.5%) BCC samples; 8/9 (89%)
BD samples; and 4/4 (100%) AK samples
• COX-2 expression (1+ or 2+) was found in normal
tissue situated ≥4 mm distant from the involved
area in 12/17 (70.6%) SCC samples; 11/32 (34.4%)
BCC samples; 6/9 (66.7%) BD samples; and 2/4
(50%) AK samples
• Alteration of COX-2 was more frequent in and
around squamous neoplasia than in other instances
• COX-2 expression was positive in skin tumours
including malignant and premalignant skin lesions;
COX-2 could be a molecular target in treating vari-
ous skin tumours
11 2013 • This study assessed CALML3 localization in normal
epidermis and in hyperproliferative skin diseases
including AK, SCC and BCC and compared
CALML3 immunoreactivity with the proliferation
marker Ki-67
• Paraffin-embedded tissue sections were examined
by IHC and analysed for localization and expres-
sion of CALML3 and Ki-67
• Increased CALML3 expression in suprabasal layers
is characteristic for differentiating keratinocytes in
normal epidermis; and nuclear expression of
CALML3 inversely correlates with expression of the
proliferation marker Ki-67
• CALML3 is a useful marker for normal and benign
hyperplastic epidermal development, whereas the
loss of nuclear CALML3 indicates progression to a
proliferative and potentially malignant phenotype
12 2012 • MTs can provide cell protection against free radi-
cals that are known to be overexpressed in a variety
of cancers
• In the epithelium adjacent to SCC, intense MT
labelling of the suprabasal layer was detected, sug-
gesting that migrating tumour cells may induce
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• This study assessed MT expression using IHC in 73
samples from SCCs, 23 samples from AKs and 20
normal skin samples
MT synthesis in healthy tissue adjacent to the
tumour
• MT may serve as a good marker of proliferation in
SCC and AK. MT overexpression in SCC may sug-
gest a potential role of MT in skin carcinogenesis
13 2012 • This preclinical study was conducted in mice carry-
ing a mesenchymal-specific deletion of CSL/RBP-
Jj, a key Notch effector, that exhibit spontaneous
multifocal keratinocyte tumours
• In human skin samples, stromal fields adjacent to
multifocal premalignant actinic keratosis lesions
exhibit decreased Notch/CSL signalling and associ-
ated molecular changes.
• Mice carrying a mesenchymal-specific deletion of
CSL/RBP-Jj, a key Notch effector, exhibit sponta-
neous multifocal keratinocyte tumours that
develop after dermal atrophy and inflammation.
• CSL-deficient dermal fibroblasts promote increased
tumour cell proliferation through upregulation of
c-Jun and c-Fos expression and consequently
higher levels of diffusible growth factors, inflamma-
tory cytokines and matrix-remodelling enzymes
• In 6-month-old mice, tumours exhibited features
of malignant SCCs, with aberrant keratinization,
pronounced dysplasia and inflammatory infiltra-
tion, and invasion of epithelial islands or spindle-
shaped cells into dermis and connective tissue
21 2009 • Expression levels of the genes BRAF and RKIP were
examined in 16 AKs and 12 SCCs by RT-qPCR
• A novel allele-specific qPCR method, in combina-
tion with direct DNA sequencing, was performed
to inspect the frequency of the V600E mutation in
exon 15, as well as to examine the mutation status
of the gene within exon 11
• BRAF and RKIP are involved in the regulation of
the RAF-1/MEK/ERK cell survival pathway. BRAF
mutations play a role in melanoma and BCC and
RKIP is downregulated in malignant melanoma
and not expressed in melanoma metastasis.
• Both BRAF and RKIP expression levels exhibit a
decrease from normal skin tissue and AK, progress-
ing to SCC
• The decrease in RKIP mRNA levels in SCC suggests
one novel mechanism in the deregulation of the
BRAF signalling pathway
• The results further indicate that BRAF does not
appear to be frequently mutated either in precan-
cerous skin lesions (AK) or in non-melanoma skin
tumours (SCC)
23 2008 • This study characterized the four betapapillo-
mavirus isolates [HPV-107, HPV-110 and HPV-
111 and FA75(KI88-03)] present in skin cancers
and investigated their clinical significance by assay-
ing their prevalence and viral load among patients
with skin lesions (n = 263)
• Used real-time PCR assays of skin biopsies
(stripped lesions and healthy skin biopsy)
• Healthy skin biopsy taken 10–15 cm from lesion,
or proximally to the ear, depending on the location
of the lesion
• Seventeen patients (6.5%) harboured ≥1 HPV types
in their lesion, vs. seven patients (2.7%) in healthy
skin
• Overall, the four viruses were more common in AK
than in healthy skin (odds ratio 5.0, 95% CI 1.4–
17.5), but the prevalence and viral loads were low
• The role of these four HPV types in carcinogenesis
remains unclear
34 2013 • This study aimed to identify pathways and genomic
alterations that are consistently involved in the for-
mation of SCCs and AKs
• RNA and DNA were isolated from SCC, AK and
normal (unexposed) epidermis from each of 13
OTRs
• Genetic sequencing of SCC and AK in OTR
patients showing early and late events on malignant
evolution
• Vast differences in gene expression profiles were
identified between SCC, AK and normal (unex-
posed) epidermis from immunosuppressed OTRs,
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• Samples were subjected to genomewide expression
analysis and genome SNP analysis
• mRNA expression results were verified by quantita-
tive PCR
with several thousand genes found to be differen-
tially expressed
• Moreover, several pathways activated in SCCs were
already activated in AKs, confirming the assump-
tion that AKs are the precursor lesions of SCC
15 2011 • This immunohistochemical analysis studied the
role of PTEN following UVB-induced DNA dam-
age
• Experiments were performed using mouse and
human tissue samples
• Formalin-fixed, paraffin-embedded human tissue
blocks were obtained from a tissue bank
• PTEN is a critical tumour suppressor
• There was a reduction in PTEN levels in human
premalignant AK and malignant SCC, supporting a
key role for PTEN in human skin cancer formation
and progression
• PTEN levels were reduced (score 0 or 1) in 92% of
AK (23/25) and 94% of invasive SCC lesions (26/
28) as compared to none of the normal skin sam-
ples (0/16)
• PTEN downregulation was significantly associated
with increasing sun damage
14 2011 • This study examined differential gene expression
among normal skin, AK and SCC
• Experiments were performed using formalin-fixed
and paraffin-embedded blocks of skin: 5 normal
(pooled), 6 from AK and 6 from SCC
• RNA was extracted and amplified, and gene expres-
sion was analysed using DNA microarray
• Significant differential gene expression (>2-fold
change, P < 0.05) was seen with 382 differentially
expressed genes between SCC and normal skin, 423
differentially expressed genes between AKs and
normal skin and 9 differentially expressed genes
between AK and SCC
• Relatively few genes were differentially expressed
between AK and SCC. The detection of these genes
using DNA microarray may assist in the differentia-
tion of AK and SCC. These genes may also poten-
tially serve as biomarkers for prognosis or
therapeutic targets in the future
17 2011 • This study compared the repetitive DNA patterns
of human AK and SCC to identify genetic alter-
ations that are associated with malignant transfor-
mation
• Eight AK and 24 SCC, which were pair-matched to
adjacent skin tissues and/or leucocytes, were evalu-
ated
• The presence of microsatellite instability and the
LOH in chromosomes 6 and 9 were investigated
using nine PCR primer pairs
• Random Amplified Polymorphic DNA patterns
were also assessed using eight primers
• Microsatellite instability was detected in two of the
eight patients with AK; the AK samples did not
exhibit an LOH
• The SCCs presented four LOHs and eight
microsatellite instabilities
• Total alterations in D6S251 microsatellites were
significantly greater in the SCC (I + II + III) com-
pared with the AK lesions (P = 0.0398)
• The altered random amplified polymorphic DNA
ranged from 70% AKs, 76% SCC-I and 90% SCC-
II, to 100% SCC-III
• The alterations that were observed in the repetitive
DNA patterns suggest a spectrum of malignant
progression from AKs to SCCs
16 2011 • This study investigated pATM expression patterns
in cultured keratinocytes, skin explants and a spec-
trum of premalignant to malignant keratinocyte
skin lesions using immunohistochemical tech-
niques
• Human AK, carcinoma in situ and SCC tissues were
obtained from tissue banks
• In several tumour types, early precursor lesions
show evidence of an activated DNA damage
response, with a diminishing response in more
advanced cancers. ATM is an important marker of
DNA damage, which becomes phosphorylated
(pATM) upon activation
• pATM expression in precancerous keratinocyte
lesions was greater and predominantly nuclear
compared with invasive lesions, where pATM was
weaker and predominantly cytoplasmic
• In AK lesions, levels of pATM were mainly equal in
the cytoplasm and nucleus (68.8%). pATM was
higher in the cytoplasm compared to the nucleus in
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6.3% of lesions and lower in the cytoplasm than in
the nucleus in 25.0% of lesions
• AKs show predominantly heavy nuclear expression
of pATM which becomes progressively less nuclear
and more cytoplasmic as the lesion evolves to more
advanced SCC
• Early, pre-invasive lesions (such as AK) express
pATM to a significantly greater extent than SCCs
• DNA damage response is active in pre-invasive
lesions (such as AK), but this mechanism is over-
ridden at a later point in the evolution of cutaneous
SCC
20 2010 • This was an analysis of the GSTM1 and T1 geno-
type of 33 participants with ≥3 solar keratoses and
of 150 controls, before and after stratification based
on smoking habits, sun exposure and immunosup-
pression
• Participants were from two regions of southern
Italy
• GSTs are enzymes involved in the defensive mecha-
nisms against oxidative stress. Polymorphisms of
GSTs have been linked with skin cancer, their asso-
ciation with AK has not yet been established
• Patients with GSTT1 (but not GSTM1) null pheno-
type were more likely to have AK in an Italian pop-
ulation (P < 0.03 for the association with GSTT1)
• This finding was in contrast with one study in an
Australian population, where the opposite was true.
The differences were attributed to ethnicity differ-
ences between the populations
18 2010 • This observational study identified and compared
the gene expression profiles of AK and SCC
• Skin biopsy specimens were taken from 16 patients
with SCC
• The specimens included 14 normal non-sun-
exposed skin samples, 14 normal sun-exposed skin
samples, 5 AKs and 15 cutaneous SCCs
• Order-restricted inference was used to analyse the
samples
• Prediction analysis of microarrays was performed
for gene selection
• Eighty-nine unique genes that most likely con-
tribute to the molecular evolution of SCC were
identified
• The model used was cross-validated using data
from a separate study and clearly distinguishes
between skin tumours (AK and SCC) and normal
skin independent of sun exposure
• Genes that were upregulated in AK and SCC were
downregulated in normal skin, and genes that were
downregulated in AK and SCC were upregulated in
normal skin
• AK and SCC are genetically related, and AK is a
precursor lesion to SCC
19 2010 • This study evaluated the effect of UVB on PTEN
expression and its underlying molecular mecha-
nisms
• Experiments were conducted using primary human
keratinocytes, human HaCaT keratinocytes and
mouse skin
• Human tissues were from formalin-fixed paraffin-
embedded blocks in replicates from three individu-
als diagnosed with AK or without skin tumours
The PTEN levels were evaluated in basal ker-
atinocytes of interfollicular epidermis
• PTEN is a critical tumour suppressor
• UVB downregulates PTEN in primary human ker-
atinocytes, human HaCaT keratinocytes and mouse
skin PTEN levels are reduced in human AK com-
pared with normal skin
• UVB downregulates PTEN in apoptotic cells
through degradation by active caspases, and in sur-
viving cells through caspase-independent but ERK/
Akt-dependent mechanisms
• The ERK/Akt/PTEN axis may form a positive feed-
back loop following UVB irradiation
22 2009 • This study used a PCR and direct sequencing
approach to assess mtDNA D-loop mutations in
two precursors, a rare keratoacanthoma and NMSC
(all tumours not related to smoking)
• The status of the tumour suppressor protein p53
was assessed using immunohistochemistry, to eval-
uate a potential association with the presence of
mtDNA mutations
• mtDNA D-loop mutations have been observed in
SCC and basal cell carcinoma of NMSC. However,
they have not been examined in SCC precursor
lesions (BD or AK)
• D-loop mutations were present in 9/36 tumours
(25%)
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• p53 mutations were present in 50% and 90% of AK
and SCC respectively but were not associated with
the presence of mtDNA mutations
• Alteration in p53 status is unlikely to contribute to
mtDNA mutagenesis
24 2008 • Mutational analysis on exons 1a, 1b and 2 of the
CDKN2A locus and exon 1 of the CDKN2B locus
as well as allelic imbalance was performed in 26 AK
specimens
• Expression levels of the genes p14(ARF), p15
(INK4b), p16(INK4a) and p53 were examined in
16 AKs and 12 SCCs by real-time PCR
• The deregulation of the expression profiles of the
CDKN2A, CDKN2B and p53 genes may, indepen-
dently of mutations and LOH at 9p21, play a signif-
icant role in AK and progression of AK to SCC
• Apart from mutations and LOH/MSI at 9p21, the
deregulation of the expression profile of the TSGs
may play a significant role in AK appearance and
progression of AK to SCC
25 2007 • This study compared gene expression changes in
AK lesions and in sun-exposed non-lesional skin
and assessed the effect of the Toll-like receptor-7
agonist, imiquimod (5% cream) on these changes
• Male subjects (n = 17) with ≥5 AK lesions on their
scalp applied vehicle or imiquimod three times a
week for 4 weeks
• Gene expression analysis was performed on skin
biopsies taken before and after treatment using an
Affymetrix oligonucleotide array
• Forty-nine genes that were suppressed or expressed
normally in sun-exposed, non-lesional skin were
significantly more suppressed in AK lesions
• Ninety-one genes that were increased or expressed
normally in sun-exposed, non-lesional skin were
further increased in expression in AK lesions
• The findings suggest that chronic UV exposure
leads to suppression of the cutaneous immune
response, perhaps partly by the induction of toler-
ance to dysplastic cells
• The gene expression changes showed abnormalities
in sun-exposed, non-lesional skin that were similar
in nature but less pronounced than abnormalities
seen in AK
26 2007 • This study examined the link between connective
and UV-damaged epithelial tissues in AK
• AK cases (n = 30) were divided into three grades
according to the proportion of dermal elastosis and
immunohistochemically analysed for the expres-
sion of Ki67, p53, p63, bcl-2, E-cadherin, 34-
betaE12 and CD99
• The increase in the solar elastosis grade was associ-
ated with an increase in positive cell numbers for
all analysed markers
• These results support the hypothesis that a gradual
evolution from slightly to severely sun-damaged
connective tissue is related to augmented epithelial
expression of apoptotic, cell proliferation and
structural proteins
• The solar elastosis grade could be a useful morpho-
logic marker in the assessment of neoplastic
changes in sun-damaged skin
27 2006 • This study explored p53 and proliferating cell
nuclear antigen expression and polyamine content
as biomarkers in skin cancer chemoprevention tri-
als
• Biopsies were collected from individuals with sun
damage on forearms (n = 78), AK on forearms
(n = 33) or previous SCC (n = 32)
• Participants with sun damage were randomized to
sunscreen or no sunscreen
• p53 expression and polyamines (involved in cell
proliferation, survival, signalling and apoptosis) in
skin were elevated in early stages of skin tumorige-
nesis and were not affected by sunscreen
• There was a stepwise and significant increase in p53
expression from biopsies without characteristics of
AK compared with early AK (P = 0.02) and AK
(P = 0.0006)
• Biomarkers like p53 expression could be useful as
predictive markers of future skin cancer risk
29 2003 • A total of 33 cases was examined for evidence of E-
cadherin promoter hypermethylation: spongiotic
dermatitis as non-neoplastic skin control (n = 9),
AK (n = 9), SCC in situ (n = 8) and invasive SCC
(n = 7)
• Silencing of e-cadherin is linked to increased
potential for tumour invasiveness and distant
metastasis This study reports silencing of e-cad-
herin in dysplastic (actinic keratosis) carcinoma
and invasive carcinoma (~58% of cases)
• Two non-neoplastic skin controls were also positive
for e-cadherin silencing. This finding may indicate
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the earliest stage of squamous carcinogenesis in
these two individuals
• E-cadherin promoter hypermethylation occurs fre-
quently and may represent an important mecha-
nism of E-cadherin inactivation in cutaneous
preneoplastic and neoplastic lesions
• The frequencies of E-cadherin promoter hyperme-
thylation appear to be correlated with more
advanced stage of squamous carcinogenesis in skin
28 2003 • A total of 33 cases were examined for evidence of
death-associated protein kinase and p16 hyperme-
thylation: spongiotic dermatitis as non-neoplastic
skin control (n = 9), AK (n = 9), SCC in situ
(n = 8) and invasive SCC (n = 7)
• Promoter methylation (i.e. inactivation) of these
genes is found in various human cancers, including
SCC of the head and neck
• Death-associated protein kinase promoter methyla-
tion was detected in one case of squamous cell car-
cinoma in situ and one case of non-neoplastic skin
control but none of the cases of invasive SCC or
AK
• P16 promoter methylation was detected in one case
of invasive squamous cell carcinoma and one case
of non-neoplastic skin control but none of the cases
of SCC in situ or AK
• Promoter hypermethylation of the death-associated
protein kinase and p16 genes does not appear to
play an important role in the development of cuta-
neous SCC
30 2002 • Five lesions of the skin, three AKs and two
AK + CIS (CIS = squamous cell carcinoma
in situ), from three patients were short-term cul-
tured and analysed cytogenetically
• Structural rearrangements involving chromosomal
band 3p13 and the centromeric region of chromo-
some 3 in AK were shown to be common features
for many types of malignant tumours, including
skin SCC, suggesting that these changes are early
genetic events associated with malignant transfor-
mation
31 1999 • Skin lesions from cases of BCC (n = 21), SCC
(n = 26), BD (n = 10) and hypertrophic AK
(n = 9) were cultured and analysed for survivin
expression using a GFP marker plasmid
• Apoptosis inhibitor survivin is expressed in many
human cancers, potentially contributing to disease
progression
• By immunohistochemistry, survivin was expressed
in 81% (17 of 21) of BCC of both nodular and
morpheaform subtypes, and in 92% (24 of 26) of
SCC.
• Survivin was also expressed in 19 premalignant
lesions of Bowen’s disease (SCC in situ) and hyper-
trophic AK, suggesting that its appearance occurs
early during keratinocyte transformation
• Apoptosis inhibition by survivin may participate in
the onset and progression of both BCC and SCC
32 1994 • Authors investigated the tumour suppressor gene
p53 in precancerous AK lesions and malignant
SCCs using polymerase chain reaction and single-
strand conformation polymorphism analysis (PCR-
SSCP) techniques
• Mutations in the tumour suppressor gene p53 were
present in 53% of AK lesions and 69% of SCCs,
suggesting that p53 mutations may be involved in
the malignant transformation of AKs to SCCs
33 1990 • To evaluate the role of HPV in the development of
premalignant lesions and cancers of the skin, 314
biopsies obtained from 227 patients with benign
neoplasms, premalignant lesions and cancers of the
• HPV-DNA is rarely detected in skin malignancies
(including AK), suggesting that HPV plays a minor
role (if any) in skin carcinogenesis in the general
population
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Similarly, altered expression of some of the genes involved in
AK development is observed in morphologically apparently nor-
mal sun-exposed skin, AK lesions and SCC.37 This has often
been described as a ‘disease continuum’ from photodamaged
skin to AK to SCC.37 In the authors’ opinion, photodamaged
skin, AK lesions and SCC can be differentiated from each other
and, therefore, the term ‘disease continuum’ is not entirely accu-
rate. It would be more accurate to talk about an association
between the initial molecular changes in individual cells and the
development of AK or SCC. The terminology disease continuum
has also been used in studies where similar histological changes
have been observed in AK lesions and adjacent skin.46 Again,
although some changes are common to both, they can be clearly
differentiated. Therefore, it is inaccurate to talk about an associ-
ation between these changes and the development of AK or SCC.
In addition, there is currently very little evidence to inform a
clinical definition of the AK field. Some of the publications iden-
tify various signs of sun damage often seen concomitantly with
AK lesions.36,47 However, a clear definition and consensus on
what constitutes visible sun damage relevant to define the AK
field is lacking.56
Based on the above, critically appraised summary statements
defining the AK field are summarized in Table 2 (‘after critical
appraisal’ column).
Thus, the majority of publications have reported on
molecular/genetic/immunological changes that take place in
UVB-exposed skin that can lead to carcinogenesis. These
provide a basic understanding on how UVB radiation affects
skin and the role it has in the pathology of AK, SCC and
other skin cancers, a knowledge that can be useful to iden-
tify new treatment targets. However, this information has
very limited applicability in clinical practice, highlighting the
existence of a clinical gap.
Expert panel clinical opinion
This literature review has highlighted a very important gap of
evidence limiting the development of a clinical definition of the
AK field, which is essential to support AK diagnosis and treat-
ment decisions.5
Until recently, the Olsen scale was the only clinical scale used
to assess AK severity.57 This scale, which grades severity/thick-
ness of individual AK lesions in isolation, combined with lesion
counts within a relatively small area, has been employed in clini-
cal trials of field therapies to assess extent of disease severity and
treatment effectiveness.57–59 However, individual lesion counts
are associated with poor reproducibility.60–62 Therefore, while
assessment of disease severity based on the Olsen scale and lesion
counts is practical, it is unreliable and inconsistent for routine
application.56
Current treatment algorithms and guidelines rely on the
Olsen scale and/or lesion counts for assessing disease extent and
providing treatment recommendations,63–65 and such guidelines
are therefore also limited for clinical practice. In clinical practice,
dermatologists need to assess the severity of AK in the entire area
affected to make a fully informed decision on optimum disease
management options.56 The need for global assessment of AK
severity, beyond individual lesion counts, has been recognized
recently by several working groups, and two novel AK severity
scales have been published.56,66 To grade disease severity, these
scales take into account the entire area affected by visible
AKs.56,66 Moreover, the importance of including visible signs of
sun damage in the AK field to assess disease severity has also
been recognized,56 highlighting the need for a clear definition of
sun damage relevant in the context of AK, which is currently
lacking.
To address this need, we have proposed a clinical definition of
field cancerization based on the results of a retrospective audit
Table 3 Continued
References Year Methodology Key findings
skin and from 25 patients with SCC of the lip were
analysed by Southern blot hybridization
• DNA probes specific for various cutaneous and
genital HPV types were used in hybridizations con-
ducted under non-stringent or stringent conditions
AK, actinic keratosis; Akt, protein kinase B; ARF, alternative reading frame; BCC, basal cell carcinoma; BD, Bowen’s disease; BRAF, B-Raf protein; BSC,
basosquamous cell carcinomas; CAF, cancer-associated fibroblasts; CALML3, calmodulin Like 3; CI, confidence interval; CDKN, cyclin-dependent kinase
Inhibitor; COX-2, cyclooxygenase-2; D-loop, displacement loop; DNA, deoxyribonucleic acid; ERK, extracellular signal-regulated kinases; FU, 5-fluorouracil;
GFP, green fluorescent protein; GST, glutathione S-transferase; GSTM1, glutathione S-transferase Mu 1; HIS, hyperspectral imaging systems; HPV, human
papillomavirus; IHC, immunohistochemistry; IMIQ, imiquimod; IRF4, interferon regulatory factor 4; LCM, laser capture microdissection; LOH, loss of heterozy-
gosity; MAL, methyl aminolevulinate; MEK, mitogen-activated protein kinase kinase; MM, malignant melanoma MMP-1, metalloproteinase-1; MT, metalloth-
ioneins; mRNA, messenger RNA; mtDNA, mitochondrial DNA; nano-ALA, 5-aminolevulinic acid; NMSC, non-melanoma skin cancer; OCT, optical coherence
tomography; OR, odds ratio; OTR, organ transplant recipient; pATM, phosphorylated ataxia-telangiectasia mutated; PBC, palisading basal cells; PCR, poly-
merase chain reaction; PD, photodamaged; PDT, photodynamic therapy; PpIX, protoporphyrin IX; PTEN, phosphatase and tensin homolog; qPCR, quantita-
tive polymerase chain reaction; RCM, reflectance confocal microscopy; RKIP, Raf kinase inhibitor protein; SA, salicylic acid; SCC, squamous cell carcinoma;
SNP, single nucleotide polymorphism; SSCP, single-strand conformation polymorphism; Tn-C, tenascin-C; TP-53, tumour protein p53; TSG, tumour suppres-
sor gene; TYR, tyrosinase; UV, ultraviolet; UVB, ultraviolet B; WRN, Werner protein.
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to identify visible signs of sun damage that are reliable indicators
of field cancerization and expert opinion (Fig. 3, top). We have
also proposed recommendations for AK management based on
this definition (Fig. 3, bottom). Prospective studies will be
needed to confirm these signs as reliable clinical indicators of
field cancerization.
Conclusion
There is a need for a clear definition of the AK field to support
AK diagnosis and treatment decisions. Here, we have reviewed a
large body of existing evidence and summarized the key sun-
induced molecular/genetic/immunological and histological
changes that take place in the AK field. However, there was a
lack of evidence in the literature to inform a clinical definition.
A clinical definition of the AK field based on reliable clinical
indicators of sun damage, as determined by retrospective audit
of AK patients and expert opinion, has been proposed.
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and sand paper) should be 
managed by 
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In the absence of
visible AK lesion(s)...
Patients with sun damage 
indicative of field of 
cancerization (clinically 
identified by telangiectasia, 
atrophy, pigmentation disorders 
and sand paper) should be 
• educated on preventive 
measures and self-
monitoring
Figure 3 Clinical definition of field cancerization and manage-
ment recommendations based on expert opinion.
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